BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Icagen, Inc. 

4222 Emperor Boulevard
Suite 350
Durham  North Carolina  27703  U.S.A.
Phone: 919-941-5206 Fax: 919-941-0813


View Clinical Trials from BioPharm Insight

Icagen, Inc. is a public biopharmaceutical company focused on the discovery, development and commercialization of novel, orally-administered, small-molecule drugs that modulate ion channel targets. Using our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates. Our two most advanced programs are:

  • ICA-105665 for epilepsy and neuropathic pain, for which we are conducting a Phase I dose-escalation study in healthy volunteers; and

  • Senicapoc, previously referred to as ICA-17043, for asthma for which we are conducting a Phase I multiple-dose study in healthy volunteers.

    We are also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. In each of these programs, we have identified small-molecule compounds that have demonstrated activity on specific ion channels. When we tested these compounds in preclinical studies, they showed desired activities and profiles, validating these ion channels as potential therapeutic targets for the particular indication. In addition to our internal programs, we have established a collaboration with Pfizer Inc focused on three sodium channel targets for the treatment of pain and related disorders. We plan to generate revenue from any product candidates that we successfully develop either through direct sales, collaboration arrangements with leading pharmaceutical and biotechnology companies, or a combination of these approaches.

    For further information, see

    Last Updated: 05-19-2008

     Key Statistics

    Ownership: Public

    Web Site: Icagen, Inc.
    Symbol: ICGN

  • Collaborations

    Pfizer  – sodium channel modulators for the treatment of pain.

     Company News
    Pfizer Inc. (PFE) Completes Acquisition of Icagen, Inc. (ICGN) 10/28/2011 9:47:22 AM
    Pfizer Inc. (PFE) Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc. (ICGN) 9/20/2011 10:38:58 AM
    Pfizer Inc. (PFE) Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc. (ICGN) 9/13/2011 10:26:18 AM
    Pfizer Inc. (PFE) Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. (ICGN) and Commencement of Subsequent Offering Period 9/6/2011 11:04:47 AM
    Pfizer Inc. (PFE) Extends Tender Offer for Icagen, Inc. (ICGN) By 1 Day; Just Short of Goal 9/1/2011 7:04:20 AM
    Icagen, Inc. (ICGN) Reaffirms Recommendation to Shareholders to Tender Shares 8/29/2011 9:52:26 AM
    Merlin Nexus and New Leaf Venture Partners Continue to Contest Proposed $56 Million Acquisition of Icagen, Inc. (ICGN) by Pfizer Inc. (PFE) 8/25/2011 10:36:17 AM
    Icagen, Inc. (ICGN) Reiterates Its Recommendation That Stockholders Accept Pfizer Inc. (PFE)'s Offer of $6 Per Share 8/16/2011 9:57:47 AM
    Icagen, Inc. (ICGN) Stockholders Send Second Letter to Board to Contest Pfizer Inc. (PFE) Acquisition Price 8/12/2011 6:55:19 AM
    Icagen, Inc. (ICGN) Reports Second Quarter 2011 Financial Results and Operational Highlights 8/10/2011 10:16:13 AM